Title:
METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-Β RECEPTOR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/270760
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating or treating steatohepatitis, comprising a curcumin derivative and a TGF-β receptor inhibitor as active ingredients. In the composition, the TGF-β receptor inhibitor inhibits the fibrosis of liver tissue, and the curcumin derivative inhibits the adipogenesis of hepatocytes increased during the fibrosis inhibition process. Thus, compared to when a curcumin derivative or a TGF-β receptor inhibitor is administered alone as in the conventional cases, the composition exhibits an excellent effect of preventing and treating steatohepatitis, and therefore, can be used as a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating or treating metabolic liver diseases, including steatohepatitis.
More Like This:
| WO/2001/035955 | BENZENE DERIVATIVES AND USE THEREOF AS DRUGS |
| JP3522754 | Polyhydric phenol compounds |
| JP6068457 | A compound and a constituent |
Inventors:
CHUNG CHOON HEE (KR)
LEE EUN SOO (KR)
HA KYUNG BONG (KR)
LEE DONG KEON (KR)
PARK NA WON (KR)
JO SU HO (KR)
LEE EUN SOO (KR)
HA KYUNG BONG (KR)
LEE DONG KEON (KR)
PARK NA WON (KR)
JO SU HO (KR)
Application Number:
PCT/KR2022/006873
Publication Date:
December 29, 2022
Filing Date:
May 13, 2022
Export Citation:
Assignee:
UNIV INDUSTRY FOUNDATION YONSEI UNIV WONJU CAMPUS (KR)
International Classes:
A61K31/12; A23L33/10; A61K31/444; A61K45/06; A61P1/16
Foreign References:
| KR101927399B1 | 2018-12-10 | |||
| KR20140104090A | 2014-08-28 | |||
| JP2007320864A | 2007-12-13 | |||
| KR101927399B1 | 2018-12-10 |
Other References:
KIM MIN-JIN, PARK SANG-A, KIM CHUN HWA, PARK SO-YEON, KIM JUNG-SHIN, KIM DAE-KEE, NAM JEONG-SEOK, SHEEN YHUN YHONG: "TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, KARGER BASEL, CH, vol. 38, no. 2, 1 January 2016 (2016-01-01), CH , pages 571 - 588, XP055776646, ISSN: 1015-8987, DOI: 10.1159/000438651
PARK, S.-A. et al. Anti-fibrotic activity of EW-7197 in CCl4-mice models of liver fibrosis by inhibition of TGF-β1/Smad signaling. 대한약학회 추계총회 및 학술대회 (The Fall International Convention of the Pharmaceutical Society of Korea). 2013, thesis abstract P1-90 (p. 265).
MIN-JIN KIM; SANG-A PARK; SO-YEON PARK; JI YEON SON; SOL-JI KIM; SEON-JOO LEE; MIN-KYUNG PARK; DAE-KEE KIM; JEONG-SEOK NAM; YHUN Y: "P-HT-02: EW-7197, a novel orally available ALK5 inhibitor inhibits hepatic fibrosis in BDL-rat model by inhibition of TGF-β1/Smad signaling", PROCEEDINGS OF THE KOREA SOCIETY OF ENVIRONMENTAL TOXICOLOGY AUTUMN INTERNATIONAL CONFERENCE 2013 [ABSTRACTS]; OCTOBER 29-30, 2013, KOREA SOCIETY OF ENVIRONMENTAL TOXICOLOGY, KOREA, 1 January 2013 (2013-01-01) - 30 October 2013 (2013-10-30), Korea, pages 706, XP009543255
PARK, S.-A. et al. Anti-fibrotic activity of EW-7197 in CCl4-mice models of liver fibrosis by inhibition of TGF-β1/Smad signaling. 대한약학회 추계총회 및 학술대회 (The Fall International Convention of the Pharmaceutical Society of Korea). 2013, thesis abstract P1-90 (p. 265).
MIN-JIN KIM; SANG-A PARK; SO-YEON PARK; JI YEON SON; SOL-JI KIM; SEON-JOO LEE; MIN-KYUNG PARK; DAE-KEE KIM; JEONG-SEOK NAM; YHUN Y: "P-HT-02: EW-7197, a novel orally available ALK5 inhibitor inhibits hepatic fibrosis in BDL-rat model by inhibition of TGF-β1/Smad signaling", PROCEEDINGS OF THE KOREA SOCIETY OF ENVIRONMENTAL TOXICOLOGY AUTUMN INTERNATIONAL CONFERENCE 2013 [ABSTRACTS]; OCTOBER 29-30, 2013, KOREA SOCIETY OF ENVIRONMENTAL TOXICOLOGY, KOREA, 1 January 2013 (2013-01-01) - 30 October 2013 (2013-10-30), Korea, pages 706, XP009543255
Attorney, Agent or Firm:
KIM, Bo Jung (KR)
Download PDF: